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Objectives: Validation of the Expanded Prostate Cancer Index Composite (EPIC) questio-
nnaire translated to Portuguese. This is an evaluation tool of the effects of treatment on 
quality of life of patients with prostate cancer.
Materials and Methods: In order to translate and validate, several recommended me-
thodological techniques in the literature were included: initial translation, synthesis of 
translation, board committee review and back translation. Sample included 40 patients 
with localized prostate cancer submitted to surgical retropubic radical prostatectomy 
from 2008 to 2010.
Results: The internal consistency analysis of the scales of the questionnaire resulted in al-
pha Cronbach coefficients “very good” (> 0.9) and “good” (> 0.8) to 8 of 14 domains. The 
higher coefficients (0.94) were assigned to sexual score, subscales incontinence and sexu-
al function. Post-operatory follow-up ranged from 3 to 35 months, median 18.7 months.
Conclusions: The Brazilian version of EPIC is reliable and valid, and is a useful tool to 
evaluate the impact of retropubic radical prostatectomy on quality of life of Brazilian 
patients with localized prostate cancer, in national and internationals studies.
INTRODUCTION
Prostate cancer is the sixth most common 
cancer in the World, representing 10% of all tu-
mors. In Brazil, it is the second most common 
cancer among men (behind non-melanoma skin 
cancer), and it is 52.350 new cases are estimated 
in 2010, or an estimated risk of 54 new cases 
per 100.000 men. The rise of incidence is due to 
the diagnosis of asymptomatic patients, the rise 
of life expectancy and the improvement of the 
information systems of the country. The inciden-
ce raised mainly in areas of the country whe-
re surveillance is common (1). The diagnosis of 
prostate cancer is made through rectal exam and 
prostate specific antigen essay (PSA) and confir-
mation with ultrasound-guided prostate biopsy. 
According to the recommendations of the Bra-
zilian Society of Urology, the preventive exam 
must be done after 45 years of age, and for those 
with family history of prostate cancer after 40 
years of age (2,3).
 Prostate cancer treatment depends of the 
staging of the disease, histological grade, patient 
age and general status of the patient. To locali-
zed tumors, surgery is an option (radical pros-
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tatectomy), as well as external radiotherapy or 
brachytherapy. To localized advanced tumors, it 
has been used surgery or radiotherapy combined 
with hormone therapy, and to metastatic disease, 
the treatment of choice is hormone therapy (4).
However, all therapeutic options have 
collateral effects (radical prostatectomy, bra-
chytherapy and external radiotherapy), such as 
urinary incontinence, erectile dysfunction and 
intestinal alterations. The evaluation of the treat-
ment must address not only the survival but the 
negative impact on quality of life of patients (5,6).
Quality of life evaluation related to health 
includes all aspects of patient evaluation and can 
verify the impact of the disease, health and treat-
ment (7). The used questionnaires to evaluate qua-
lity of life are useful to transform subjective mea-
sures in objectives evaluations in order to quantify 
and analyze specific and global aspects (8,9).
World Health Organization (WHO) defines 
quality of life as the individual perception of his 
role in life, in relation to his (her) objectives, expec-
tations, patterns and worries, in culture and values 
contexts. It is a broad and complex concept that 
encompass physical health, psychological status, 
independence level, social relations, personal belie-
fs, and relation to environment (10,11).
MATERIALS AND METHODS
EPIC questionnaire is a self-administered 
tool and is intended to evaluate the impact of tre-
atment on quality of life of patients with prostate 
cancer. It includes 50 questions, of four domains: 
urinary, intestinal, sexual and hormonal; it evalu-
ates the last four weeks and includes a Likert scale 
of answers of 5 options. Each domain contains two 
subscales (function and nuisance). The urinary do-
main still has two additional subscales: incontinen-
ce and irritative/obstructive symptoms (12).
Procedures for translation and validation
 The translation and validation of the 
questionnaire was performed in four steps: ini-
tial translation, translation synthesis, board 
committee of specialists review and back trans-
lation, according to the criteria described by 
Guillemin et al (13).
Initial translation
 Question translation was performed by two 
independent translators, fluent in English and aware 
of the study objectives.
Translation Synthesis
 Production of a synthesis of the two transla-
ted versions carried out by the researcher and leader, 
maintaining the same fundamental characteristics of 
the original questionnaire.
Review by a Board of Specialists Committee
 A committee of specialists included five 
urologists fluent in English that evaluated for 
each question the semantic, idiomatic, cultural 
and conceptual equivalents between the original 
and the translated version.
Semantic equivalence refers to the me-
aning of the words (grammar and vocabulary), 
while idiomatic equivalence refers to colloquial 
expressions that are equivalent to the original 
idiom. Cultural equivalence refers to the lived ex-
periences in the cultural context of society. The 
conceptual equivalence refers to the words with 
different cultural meaning (14).
 A first final version in Portuguese was 
proposed during the meeting of the panel of spe-
cialists, the leader and the researcher, after joint 
evaluation of instructions, questions and format.
Back Translation
During back translation, the questionnaire 
was translated again, but this time from Portugue-
se to English, by two native English translators 
with domain of the Portuguese language, who did 
not know the objectives of the study or the origi-
nal questionnaire. Afterwards, they compared the 
translation with the original and did not find any 
discrepancy.
Population and Sampling
 The sample included 40 male patients ran-
domly selected in the ambulatory of Urology of Hos-
pital São Paulo, with the following inclusion criteria: 
a) diagnosis of localized prostate cancer; b) clinical 
stage T1 or T2; c) did not receive any previous treat-
ment for prostate cancer; d) therapeutic indication of 
retropubic radical prostatectomy.
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Ethical Aspects
 Initially, an e-mail authorization was refer-
red to the authors of EPIC in order to translate and 
validate the original to Portuguese. After that autho-
rization, the research was approved by the Ethical 
Committee of Research of the Federal University of 
São Paulo. All patients signed an Informed Consent.
Statistical analysis
In this phase, the same procedure adopted 
by the original EPIC study was performed, allowing 
the evaluation of a total sample of heterogeneous 
patients regarding the impact of treatment on the 
domains: urinary, intestinal, sexual and hormonal. 
The tests were performed using the quality of life 
scores obtained after treatment.
 To internal consistency analysis, in order to 
verify the reliability of the instrument (15), it was 
used the statistical alpha test of Cronbach (16). This 
index varies from 0 to 1. The closest to 1, the higher 
the reliability of the instrument. Intern consistency 
was considered: very good, if superior to 0.9; good, 
between 0.8 and 0.9; reasonable, between 0.7 and 
0.8; weak, between 0.7 and 0.8; and poor, between 
0.6 and 0.7; it was considered inadmissible if inferior 
to 0.6. It there is no variance between the individual 
items, the alpha score is 1: all items of the instru-
ment are totally homogeneous, producing exactly 
the same variance (17,18).
The significance level for the statistical 
tests was 5%, or p < 0.05. Data analysis was made 
using the software SPSS - Statistical Package for 
Social Science.
RESULTS
Socio-demographic characteristics of the 40 
patients are described in Table-1. Median age was 
63.8 ± 8.6 years, varying from 46 to 78 years, and 
70% of patients were married or had a fixed partner.
 Table-2 depicts the results of intern con-
sistency, median and standard deviation for the 
14 domains (4 summaries and 10 subscales) of the 
Brazilian version of EPIC. The internal consistency 
analysis of the scales of the questionnaire resulted in 
Cronbach alpha coefficients “very good” above 0.9 
and “good” above 0.8 to 8 of them, and the higher 
scores were obtained for the sexual score, subscales 
incontinence and sexual function. When we com-
pared these data with the original version and the 
Spanish version (Table-3), it is observed that they are 
similar, without significant differences.
Table-4 shows the data for patients older 
than 65 or with less than 65 years and EPIC scores. It 
is observed that as the age rises, there is a decline of 
the scores “sexual domain”, ‘sexual function”, “in-
continence” and “urinary distress”.
Table 1 - Socio-demographic profile.
Age
Median 63.8%
Standard Deviation 8.6
Minimum 46
Maximum 78
Colour / Race
White 42.5%
Black 42.5%
Brown 15.0%
Marital Status
Married/fixed partner 70.0%
Single 12.5%
Widow 15.0%
Divorced 2.5%
Schooling
Illiterate / Incomplete basic school 35.0%
Complete basic school/Incomplete 
high school 
35.0%
Complete high school /Incomplete 
higher education
20.0%
Complete higher education 10.0%
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 Post-operatory follow-up varied from 3 
to 35 months, median 18.7 months, with mi-
nimal significant correlations of the following 
EPIC scores: “domain and urinary function”, “ir-
ritative/obstructive”, “domain, function and in-
testinal distress” and “hormonal distress”). It is 
observed that as the time passes, the scores tend 
to decrease (Table-5).
DISCUSSION
The literature highly recommends the 
adaptation of scales and questionnaires previous-
ly validated, due to reduction of costs, a standar-
dization of measure for investigation in different 
cultures, allowing international studies to compa-
re the same phenomena in several cultures (19).
Table 2 - Descriptive measures of EPIC.
HRQOL Domain Number of itens Mean Score (sd) Internal consistency 
reliability
HRQOL Domain Summary Scores
Urinary 12 82.2 (12.1) 0.87
Bowel 14 96.7 (2.1) 0.81
Sexual 13 35.2 (16.3) 0.94
Hormonal 11 94.0 (9.2) 0.74
Domain-Specific HRQOL Subscales
Urinary Subscales
Function 5 82.9 (14.9) 0.69
Bother 7 81.7 (11.0) 0.84
Incontinence 4 73.0 (8.7) 0.94
Irritative/Obstructive 7 89.3 (9.5) 0.78
Bowel Subscales
Function 7 96.2 (2.5) 0.53
Bother 7 97.1 (1.6) 0.87
Sexual Subscales
Function 9 29.1 (14.0) 0.94
Bother 4 48.9 (13.1) 0.93
Hormonal Subscales
Function 5 89.7 (12.8) 0.57
Bother 6 97.6 (2.0) 0.66
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 After careful review of literature, in order 
to identify all available instruments for the evalua-
tion of the impact of treatment of prostate cancer in 
quality of life, EPIC questionnaire was chosen, since 
it was the one that best approached our goals and 
was highly accepted in the international scientific 
community, and easy to use. Since EPIC was develo-
ped to the American population, it was necessary to 
translate it and adapt it to Brazilian context and to 
test its measure proprieties.
Final version of translated EPIC (Appendix) 
maintained the English original title, since it is inter-
nationally recognized. It was added “Brazilian Ver-
sion” to the title to facilitate the search in data bases.
Table 4 - Correlation of EPIC score and age.
HRQOL Domain < 65 years (a)
(n = 23)
≥ 65 years (b)
(n = 17)
p value between (a) 
and (b)
Mean Sd Mean Sd
HRQOL Domain Summary Scores
Urinary 81.2 7.5 75.2 13.5 0.08
Bowel 95.7 3.1 96.2 1.7 0.55
Sexual 40.4 15.7 28.1 17.7 < 0.03
Hormonal 90.9 11.3 90.7 9.1 0.95
Domain-Specific HRQOL Subscales
Urinary Subscales
Function 81.4 10.5 75.0 17.4 0.16
Bother 81.2 5.9 75.2 12.1 < 0.04
Incontinence 77.6 8.1 66.9 9.4 < 0.00
Irritative/Obstructive 85.9 4.2 86.5 12.9 0.84
Bowel Subscales
Function 94.0 3.5 96.3 2.5 < 0.03
Bother 97.0 2.0 96.2 0.8 0.13
Sexual Subscales
Function 35.3 14.1 20.7 14.5 < 0.00
Bother 51.9 14.0 44.9 12.1 0.11
Hormonal Subscales
Function 86.1 15.5 84.8 9.8 0.76
Bother 95.7 0.9 94.9 1.0 < 0.01
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Tabela 5 - Correlation between the score and the EPIC segment postoperatively.
HRQOL Domain < 12 months (a)
n = 14
≥ 12 months (b)
n = 26
p value between 
(a) and (b)
Mean Sd Mean Sd
HRQOL Domain Summary Scores
Urinary 73.9 9.5 81.6 10.7 < 0.03
Bowel 99.2 1.6 95.0 3.0 < 0.00
Sexual 35.1 14.9 35.2 17.3 0.99
Hormonal 91.5 11.1 92.8 9.5 0.70
Domain-Specific HRQOL Subscales
Urinary Subscales
Function 70.6 7.3 83.2 14.4 < 0.00
Bother 75.6 10.7 80.3 7.6 0.11
Incontinence 69.5 6.4 74.9 10.2 0.08
Irritative/Obstructive 79.5 11.3 88.1 7.0 < 0.01
Bowel Subscales
Function 98.2 2.5 94.4 3.6 < 0.00
Bother 99.9 0.0 95.6 2.5  0.00
Sexual Subscales
Function 29.9 13.6 28.7 14.7 0.80
Bother 46.9 11.6 50.0 14.2 0.49
Hormonal Subscales
Function 88.4 16.1 89.2 11.9 0.86
Bother 94.6 1.5 97.4 1.4 < 0.00
 The patients that answered the questio-
nnaire were invited to answer open question re-
garding each item in order to identify questions 
with difficult understanding. In general, the ins-
trument was easy to apply and well accepted by 
the patients, with good efficacy.
 The results obtained in the current stu-
dy are consistent with the original and indica-
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te equivalency with the Brazilian version, with 
adequate reliability, high sensitivity to altera-
tions. However, it is important to state that the 
questionnaire was used only for patients sub-
mitted to retropubic radical prostatectomy. In 
the present, another study comparing “open” to 
robotic-assisted laparoscopic radical prostatec-
tomy is been carried out.
This questionnaire, after comparision of 
treatments, will be a resourceful tool for clini-
cals and researchers, to evaluate the impact of 
different treatmens on quality of life of pacients 
with prostate cancer.
CONCLUSIONS
Brazilian version of EPIC is valid and re-
liable as a new tool for the evaluation of the 
impact of retropubic radical prostatectomy in 
quality of life of Brazilian patients with locali-
zed prostate cancer, for national and internatio-
nal studies.
APPENDIX
The Expanded Prostate Cancer Index 
Composite (EPIC) – Brazilian version – Availa-
ble at:
http://www.uroepm.com.br/setores/robotica.html
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